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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of pharmacotherapy and behavioural interventions enacted in the lead-up to the school return during autumn
which are designed to reduce asthma exacerbations in school-aged children during this period.
B A C K G R O U N D
Description of the condition
Asthma is a chronic disease of the airways characterised by recur-
rent episodes of wheezing, breathlessness and cough, together with
variable expiratory airflow limitation. Symptoms are frequently
associated with airway inflammation and bronchial hyperrespon-
siveness (GINA 2016). Asthma can affect people of all ages, al-
though childhood onset is common. Asthma is diagnosed clini-
cally based upon evaluation of symptoms and response to phar-
macotherapy. There is no specific diagnostic test, although spiro-
metric measurement of reversible airflow limitation and indirect
or direct tests of airway hyperresponsiveness can be useful (GINA
2016).
Currently, the number of people with asthma globally is estimated
to be approximately 300 million; this number is predicted to
be closer to 400 million by 2025 (WHO 2007). Asthma is the
most common chronic disease among children (Asher 2014). The
ISAAC study in 2002 to 2003 found the highest prevalence of
childhood wheeze in Latin and North America, and in English-
speaking countries in Australasia and Europe (Asher 2006). Cur-
rently, more than a million children (one in eleven) in the UK are
believed to be living with asthma (Asthma UK 2016).
Symptom exacerbations can be triggered by a number of environ-
mental challenges including pollutants (Lierl 2003; Schildcrout
2006), physical activity (Randolph 2013), and respiratory in-
fections or allergens (Brandt 2015; Ito 2015; Murray 2006;
Olenec 2010). People whose airway inflammation is not ade-
quately controlled are more vulnerable to exacerbations than those
on adequate therapy with good treatment adherence. Poorly con-
trolled day-to-day asthma symptoms can limit activities, includ-
ing schooling, and impair sleep quality and overall quality of life
(Kiotseridis 2013; Teyhan 2015; van Maanen 2013). However, it
is asthma exacerbations - acute or subacute progressive worsening
of symptoms (NAEPP 2007) - which pose the greatest danger to
people with asthma. Asthma exacerbations are also associated with
reduced school or work attendance and are the most important
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contributor to the economic and social costs of asthma (Bahadori
2009; Hoskins 2000; Ismaila 2013).
A seasonal peak in exacerbation rates has been consistently demon-
strated in the autumn acrossmultipleNorthernHemisphere coun-
tries (Fleming 2000; Gergen 2002). More specifically, exacerba-
tion rates peak in September following the summer school holiday
and in line with the start of the autumn term (Johnston 2006).
Equivalent peaks during February have been reported in Southern
Hemisphere countries (Lincoln 2006; Lister 2001). The autumn
peak in asthma exacerbations is temporally linked to children re-
turning to school and most pronounced in school-aged children
(Corne 2002). Hospitalisations and emergency department visits
attributable to asthma demonstrate an initial peak in school-aged
children; however this is followed within days by increased hospi-
talisations in preschool children and amore blunted peak in adults
up to the age of 50 years (Sears 2008). There is evidence that viral
infections, particularly rhinovirus, may contribute to this season-
ality (Johnston 1996; Johnston 2005; Thumerelle 2003); but also
that sub-optimal asthma treatment may be a contributing factor
(Johnston 2005). Not only do viral infections trigger asthma ex-
acerbations but there is also evidence that asthmatic individuals
are more susceptible to rhinovirus infection than those without
asthma (Baraldo 2012; Wark 2005). Individuals at particular risk
of asthma exacerbation have been identified as those with more
severe disease, greater degree of atopy, and recent exacerbations
(Teach 2015b).
Description of the intervention
A number of interventions including asthma education pro-
grammes, action plans, self-monitoring, and self-initiation of oral
corticosteroid treatment have been shown to reduce both symp-
tom exacerbations and need for unscheduled acute care in chil-
drenwith asthma (Bhogal 2006;Guevara 2003; Vuillermin 2011).
Given that the seasonality of asthma exacerbations in school-aged
children is predictable and repeatable, it is reasonable to assume
that management strategies which anticipate increased risk in the
autumn might reduce exacerbation frequency during this period.
Whilst the exact aetiology of the seasonal peak in asthma exacer-
bations is not fully understood, any change in management aimed
at improving asthma control in anticipation of the autumn school
return, if successful, could offer protection against the increased
risk recognised to be associated with this event. Therapies that
have demonstrated to reduce the seasonal excess of exacerbations
in the autumn, in addition to the annual number of exacerbations,
include year-round treatment with the anti-IgE monoclonal anti-
body, omalizumab (Busse 2011); or with high-dose inhaled corti-
costeroids (Szefler 2008). Omalizumab is, however, an expensive
treatment, whilst high-dose inhaled corticosteroids are associated
with adverse effects upon growth and bone health (Sharek 2000;
Wong 2000).
Given the pragmatic difficulties associated with minimising viral
or allergen exposure, two main potential strategies remain which
might reduce autumn asthma exacerbations whilst minimising
treatment costs and adverse effects. The first strategy would be
to add on, or increase, asthma pharmacotherapy before the au-
tumn period; and the second strategy would be to focus upon
treatment adherence and achieving symptom control before and
during the autumn. It is anticipated that the greatest benefit from
an intervention targeting seasonal exacerbations would be gained
by school-aged children since the autumn peak in exacerbations
is most pronounced in this age group. Similarly, greater benefit
might be demonstrable in those at increased risk of exacerbation
due to poor treatment adherence, disease severity, allergic pheno-
type or recent exacerbation.
Add-on therapies include those aimed at reducing airway inflam-
mation, such as corticosteroid preparations, macrolide antibiotics
or leukotriene receptor antagonists. Alternatively, agents such as
biologicswhichmore specifically target the interactionbetween the
immune response and viral infection might be selected (Durrani
2012; Gill 2010). Important considerations with respect to choice
of intervention include onset of action and ease of administration,
in addition to cost and adverse effect profile.
Strategies to improve treatment adherence require adherence sta-
tus to be assessed, and barriers leading to non-adherence to be
identified and addressed. The success of adherence interventions
can be increased by a number of strategies, including providing
biofeedback (Feldman 2012), and increasing motivation via moti-
vational interviewing techniques (Borrelli 2007). Nevertheless it is
difficult to achieve sustained adherence (Jonasson 2000). Target-
ing adherence interventions to periods of increased exacerbation
risk might increase their overall success.
How the intervention might work
Since the greatest peak in exacerbation rates is observed amongst
school-aged children this potentially implicates some aspect of the
school environment in the aetiology of the seasonal peak. Upon re-
turn to school in the autumn children are exposed to allergens and
respiratory infections by close contact with their classmates (Cai
2011; Krop 2014). Moreover, it has been suggested that changes
in routine during the summer holidays and lower perceived risk
of cold weather or respiratory infection might be associated with
both intentional reduction in preventer medication and poten-
tially poorer adherence (Johnston 2005; Sears 2008). During the
autumn months mould spores, which can act as a trigger for aller-
gic asthma, are more abundant than at other times of the year (de
Ana 2006). However, the sequential periods of peak risk demon-
strated by school-aged children, younger children and adults sug-
gest a transmissible agent is responsible. In support of this are
findings from virological studies that demonstrate increased vi-
ral isolations during autumn, notably rhinovirus, from children
with asthma compared to those without, with the highest rates of
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isolation measured in those admitted to hospital with an asthma
exacerbation (Johnston 2005; Thumerelle 2003).
There is also evidence that baseline asthma control and treatment
adherence might predict those most at risk. A higher rate of ex-
acerbation has been reported in people prescribed bronchodila-
tor therapy alone than in those prescribed an inhaled steroid or
other preventer medication (Johnston 2005; Murray 2006). Fur-
thermore, school-aged children with mild asthma but poor con-
trol, as evidenced by an exacerbation during the run-in period of
4 to 9 months, experienced a significant reduction in exacerbation
frequency within a trial of seasonal omalizumab treatment (Teach
2015a). Exacerbation rate could not be significantly reduced in
those with mild asthma but without a recent admission (Teach
2015a). Potentially any intervention based upon reinforcing or
increasing adherence to regular treatment, monitoring symptoms
to assess control or a seasonal enhancement of treatment might
reduce ongoing airway inflammation and the likelihood of viral
infection triggering an exacerbation.
Why it is important to do this review
Although the asthma epidemic observed in the 1980s and 1990s
appears to have stabilised, a study from the NorthernHemisphere
demonstrates that emergency care contacts due to asthma remain
significantly higher in September than in other months (Larsen
2016). The recent trial of seasonal omalizumab administration
demonstrated a significant reduction in exacerbation frequency
amongst children with either severe asthma or poorly controlled
mild to moderate disease (Teach 2015a). However, it is important
to identify whether a similar effect can be achieved with less inva-
sive and less expensive medications, particularly since in countries
such as the UK, omalizumab can only be prescribed to people
meeting strict severity criteria. It is estimated that up to 25% of
annual hospitalisations for asthma occur in September (Johnston
2006). Moreover, acute exacerbations are the principal driver of
the economic and social costs of asthma (Bahadori 2009; Hoskins
2000; Ismaila 2013). Therefore, interventions based upon an an-
ticipatory change in asthma management, if successful, could sub-
stantially reduce both the overall exacerbation rate and the strain
placed upon health services by multiple exacerbations during a
relatively short period of time.
O B J E C T I V E S
To assess the effects of pharmacotherapy and behavioural interven-
tions enacted in the lead-up to the school return during autumn
which are designed to reduce asthma exacerbations in school-aged
children during this period.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), quasi ran-
domised controlled trials and observational studies. We will in-
clude studies reported as full-text, those published as abstract only,
and unpublished data.
Types of participants
We will include studies which present data relating to school-aged
children, 5 to 18 years old, with asthma. This is in recognition
of the absence of a significant autumn peak in exacerbations in
adults. We will also exclude studies of children below the age of
5 given the likely different aetiology and responses to treatment
in preschool children; notably the high prevalence of wheezing in
response to viral infection unresponsive to conventional inhaled
or oral steroid asthma treatment.
Types of interventions
Wewill include studies comparing interventions aimed specifically
at reducing autumn exacerbations with usual care where there is
no systematic change in management in preparation for school
return. Eligible interventions will include pharmacotherapy trials
and behavioural or educational-based initiatives. Observational
studies may have no usual care comparison group.
Types of outcome measures
Primary outcomes
For controlled trials the primary outcome, depending uponwhat is
reported, will be number of participants experiencing one or more
asthma exacerbation during the autumn period (the first three-
month period following the autumn school return) or during the
intervention period if this includes the autumn months. An exac-
erbation will be defined as increased asthma symptoms requiring
treatment with oral steroids or hospitalisation.
In observational studies, where theremay be no usual care compar-
ison group, we will assess the relative number of participants expe-
riencing asthma exacerbations during the autumn months (stan-
dardised as the first three months following the autumn school
return) compared to the remainder of the year.
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Secondary outcomes
1. Number of participants experiencing exacerbations of
asthma requiring hospitalisation.
2. Number of participants experiencing exacerbations of
asthma requiring paediatric intensive care (PICU) admission.
3. Number of asthma-related deaths.
4. Asthma control, measured by standardised tool (e.g.
Childhood Asthma Control Test (cACT) or Asthma Control
Test (ACT)).
5. Asthma-related quality of life measured by standardised tool
(e.g. Paediatric Asthma Quality of Life Questionnaire (PAQLQ)
or Asthma Quality of Life Questionnaire (AQLQ)).
6. Days of schooling (or employment for those beyond school
age) missed.
7. Adverse events (including serious adverse events).
Secondary outcomes will only be considered in controlled trials.
For each outcome data will be collected throughout the autumn
period or the intervention period (as for the primary outcome) in
both the intervention group and the standard therapy group. The
number of young people requiring hospitalisation, PICU admis-
sion and number of asthma-related deaths as well as average ques-
tionnaire score, number of days education/employment missed or
adverse events will be recorded.
Reporting the primary outcome is not required as an inclusion
criterion for the review.
Search methods for identification of studies
Electronic searches
Wewill identify trials from theCochrane AirwaysGroup’s Register
of controlled clinical trials (CAGR), which is maintained by the
Information Specialist for the Group. The Register contains trial
reports identified through systematic searches of multiple biblio-
graphic databases and handsearching of respiratory journals and
meeting abstracts (please see Appendix 1 for further details). We
will search all records in the CAGR using the search strategy in
Appendix 2.
We will also conduct a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials
portal (www.who.int/ictrp/en/). We will search all databases from
their inception to the present, and we will impose no restriction
on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (KP, KH) will independently screen titles and
abstracts for inclusion of all the potential studies we identify as a
result of the search and code them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We will retrieve the full-
text study reports/publication and two review authors (KP, KH)
will independently screen the full-text and identify studies for in-
clusion, and identify and record reasons for exclusion of the ineli-
gible studies. We will resolve any disagreement through discussion
or, if required, we will consult a third review author (DK). We will
identify and exclude duplicates and collate multiple reports of the
same study so that each study rather than each report is the unit
of interest in the review. We will record the selection process in
sufficient detail to complete a PRISMA flow diagram and ’Char-
acteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in
the review. Three review authors (KP, KH, DK) will extract study
characteristics from included studies in duplicate. We will extract
the following study characteristics.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (KP, DK) will independently extract outcome
data from the included studies. We will note in the ’Characteristics
of included studies’ table if outcome data was not reported in
a usable way. We will resolve disagreements by consensus or by
involving a third review author (KH). One review author (KP)
will transfer data into the Review Manager file (RevMan 2014).
We will double-check that data is entered correctly by comparing
the data presented in the systematic review with the study reports.
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A second review author (DK) will spot-check study characteristics
for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (KP, KH) will independently assess the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another review author (DK).We will assess the risk of bias accord-
ing to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgment in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgments across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations form it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous
data as mean difference or standardised mean difference. We will
enter data presented as a scale with a consistent direction of effect.
We will undertake meta-analyses only where this is meaningful,
such as when the treatments, participants and underlying clinical
question are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
same meta-analysis, we will halve the control group to avoid dou-
ble-counting.
Unit of analysis issues
Asthma exacerbations will be considered a dichotomous outcome
using participants as the unit of analysis. The odds of exacerbation
in the intervention group during the intervention will be com-
pared to the odds of exacerbation in individuals receiving standard
therapy. For large-scale behavioural interventions (e.g. those that
involve contacting young people in late summer to remind them
of the need for treatment adherence), the unit of allocation may
be primary care practice level rather than at the level of the indi-
vidual. Where this is the case, results will only be included if the
original trial accounted for clustering or if it is possible to adjust
for this by calculating a design effect.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will explore the impact of including
such studies in the overall assessment of results by a sensitivity
analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity (I² >
50%) we will report it and explore possible causes by pre-specified
subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small-study and publication
biases.
Data synthesis
We will use a Mantel-Haenszel random-effects model using Re-
view Manager software (RevMan 2014) for all outcomes as we
expect variation in effects due to differences in study populations
andmethods (Mantel 1959).We will perform a sensitivity analysis
with a fixed-effect model when we encounter significant hetero-
geneity.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the follow-
ing outcomes: exacerbation occurrence (requiring oral steroids or
hospitalisation); hospitalisation; PICU admission; asthma-related
deaths; asthma control; asthma-related quality of life; days off
school/employment missed; and adverse events. We will use the
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five GRADE considerations (study limitations, consistency of ef-
fect, imprecision, indirectness and publication bias) to assess the
quality of a body of evidence as it relates to the studies which con-
tribute data to the meta-analyses for the pre-specified outcomes.
We will use methods and recommendations described in Section
8.5 and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011) usingGRADEproGDT soft-
ware. We will justify all decisions to down- or up-grade the quality
of studies using footnotes and we will make comments to aid the
reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We recognise that intervention type or disease or severity might
affect effect size and therefore plan to carry out the following
subgroup analyses for all outcomes:
1. An analysis separating studies based upon pharmacological
interventions from those based upon non-pharmacological
interventions.
2. Analyses considering separately those with mild to
moderate disease (intermittent bronchodilator only; or low/
moderate inhaled steroids with or without a single add-on
therapy) and those with severe asthma (high-dose inhaled
steroids; or two or more add on therapies).
(High inhaled steroid dose beclomethasone equivalents daily: 5 to
12 years ≥ 800 mcg, older than 12 years ≥ 2000 mcg).
We will use the identical primary and secondary outcomes in sub-
group analyses as in the main analysis.
We will use the formal test for subgroup interactions in Review
Manager 5 to determine statistical significance of subgroup anal-
yses (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses:
1. An analysis including only studies without missing data.
2. An analysis excluding cluster randomised trials (in case any
benefit in cluster randomised trials arises due to the ’herd’ effect
of an intervention).
We will also re-run analyses and compare results after sequential
exclusion of each study from any meta-analysis.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
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(Continued)
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
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Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Seasons
#6 seasonal*:ti
#7 (season* NEAR (symptom* or vari* or exacerbat* or peak*)):ti,ab
#8 ((Autumn or Fall or summer or September or February) NEAR (symptom* or vari* or exacerbat* or peak*)):ti,ab
#9 MeSH DESCRIPTOR Schools Explode All
#10 (school* NEAR (holiday* or vacation* or return* or resume* or term* or year* or start*)):ti,ab
#11 #5 or #6 or #7 or #8 or #9 or #10
#12 #4 AND #11
[Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, asthma]
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